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Abstract
The development of hepatocellular carcinoma (HCC) in persons who are persistently infected with
hepatitis C virus (HCV) is a growing problem worldwide. Current antiviral therapies are not
effective in many patients with chronic hepatitis C, and a greater understanding of the factors
leading to progression to HCC will be necessary to design novel approaches to prevention of
HCV-associated HCC. The lack of a small animal model of chronic HCV infection has hampered
understanding of these factors. Since HCV is an RNA virus with little potential for integration of
its genetic material into the host genome, the mechanisms underlying HCV promotion of cancer
are likely to differ from other models of viral carcinogenesis. In patients persistently infected with
HCV, chronic inflammation resulting from immune responses against infected hepatocytes is
associated with progressive fibrosis and cirrhosis. Cirrhosis is an important risk factor for HCC
independent of HCV infection, and a majority of HCV-associated HCC arises in the setting of
cirrhosis. However, a significant minority arises in the absence of cirrhosis, indicating that
cirrhosis is not a prerequisite for cancer. Other lines of evidence suggest that direct, virus-specific
mechanisms may be involved. Transgenic mice expressing HCV proteins develop cancer in the
absence of inflammation or immune recognition of the transgene. In vitro studies have revealed
multiple interactions of HCV-encoded proteins with cell cycle regulators and tumor suppressor
proteins, raising the possibility that HCV can disrupt control of cellular proliferation, or impair the
cell's response to DNA damage. A combination of virus-specific, host genetic, environmental, and
immune-related factors are likely to determine the progression to HCC in patients who are
chronically infected with HCV. Here, we summarize current knowledge of the virus-specific
mechanisms that may contribute to HCV-associated HCC.
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Introduction
Liver cancer is the 3rd leading cause of cancer deaths worldwide. While incidence rates are
stable or declining for many types of cancers, they have increased substantially for
hepatocellular carcinoma (HCC) in recent years in both Japan and the U.S. In Japan, the
age-adjusted annual death rate due to primary liver cancer rose from ∼10/100,000 persons in
1975 to a peak of 27.5 in 2002, attributable in large part to increases in the prevalence of
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hepatitis C virus (HCV) infection that occurred decades earlier, in the aftermath of World
War II (Tanaka et al 2002, Umemura et al 2009, Yoshizawa 2002). HCV infection now
accounts for approximately 70% of cases of liver cancer in Japan. The incidence of liver
cancer has also undergone a remarkable increase in the U.S., where extensive spread of
HCV occurred approximately 30 years later (Tanaka et al 2002). Between 2001-2006, the
incidence of microscopically-confirmed HCC increased at an average annual percentage rate
of 9.1% among persons aged 50-59 years (Centers for Disease Control and Prevention,
2010). Increased rates of HCC are particularly striking among African American and
Hispanic males, reflecting racial disparities in the prevalence of chronic HCV infection, now
the leading cause of HCC within the U.S. (Altekruse et al 2009, Armstrong et al 2006).
While there are good statistics for the U.S. and Japan, it is difficult to estimate the global
burden of HCV-associated liver cancer. In one analysis, HCV infection accounted for
155,000 liver cancer deaths in 2002 (Perz and Alter 2006), but such a figure is likely to
significantly underestimate the numbers of HCV-associated HCC deaths today.
Despite advances in therapy for HCC, 1-year survival rates remain less than 50% in the U.S.
(Altekruse et al 2009). Even in Japan, where early diagnosis and potentially curative
interventions are common, recurrence is frequent and the long-term prognosis poor
(Masuzaki et al 2008). Antiviral therapies may prevent progression to HCC in HCV-infected
persons, but current interferon-based standard-of-care therapies eliminate the virus in only
half of those treated (McHutchison and Fried 2003). Moreover, the preventive benefits of
interferon therapy are limited in the absence of virus eradication (Lok et al 2009). Newer,
direct-acting antiviral agents are on the horizon and will significantly improve treatment
outcomes, but rapid selection of resistant viruses will mandate continued reliance on
interferon as the foundation of therapy, at least for the near term future (Shimakami et al
2009). Importantly, only a small proportion of infected persons are likely to have access to
these therapies in most countries. The population of persons within the U.S. who have been
infected with HCV for more than 2 decades and who are at highest risk of HCC is thus
likely to continue to grow over the next 20 years, fueling continued increases in HCC
incidence (Davis et al 2010). Worldwide, 130-170 million people worldwide are chronically
infected with HCV (Lavanchy 2009).
Direct vs. indirect carcinogenic mechanisms
Most persons who are infected with HCV fail to clear the virus, and become persistently
infected and thus at long-term risk for progressive hepatic fibrosis, cirrhosis, or HCC
(reviewed in Lemon et al 2007). HCV is a positive-strand RNA virus that replicates in the
cytoplasm and has little potential for integration of its genome into cellular DNA. The
presence of cirrhosis and chronic hepatic inflammation with associated oxidative stress and
accompanying potential for cellular DNA damage are unquestionably important contributing
causes to HCV-associated HCC (Bartsch and Nair 2004, Nakamoto et al 1998, Okuda et al
2002). However, there are several lines of evidence supporting a direct role for HCV in
cancer promotion. First, although direct comparisons are limited, the incidence of HCC
appears to be greater in HCV-associated cirrhosis (7-13% over 5 years) (Degos et al 2000,
Lok et al 2009) than in cirrhosis resulting from autoimmune hepatitis (Teufel et al 2009,
Yeoman et al 2008). Moreover, there is an increasing recognition that HCV-associated HCC
may arise in the absence of cirrhosis, albeit at a much lower rate than in patients with
cirrhosis (Bralet et al 2000, Lok et al 2009, Yeh et al 2010). The occurrence of HCC in some
lineages of transgenic mice also provides compelling evidence that HCV protein expression
may be directly oncogenic (Lerat et al 2002, Moriya et al 1998).
An important question is whether cancer arises in an infected hepatocyte, or in uninfected
bystander hepatocytes that are present in far greater numbers in the HCV-infected liver.
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Estimates based on observed genome copy numbers in the livers of HCV-infected
chimpanzees suggest that less than 30 percent of hepatocytes contain replicating virus
(Bigger et al 2004). This is consistent with the 2-20% of cells in which we observed HCV
antigen expression by two-photon microscopy of frozen sections of nonmalignant liver
tissue (Liang et al 2009). The proportion of hepatocytes expressing the Ki67 proliferation
marker is increased in advanced hepatitis C (Farinati et al 1996, Koskinas et al 2005), and a
case-control study suggests that patients with a high proportion of Ki67-positive hepatocytes
are at increased risk for HCC (Dutta et al 1998). However, it is not known whether the
proliferating hepatocytes are infected with HCV, or alternatively, whether they are
uninfected cells proliferating in response to the loss of infected cells due to virus-induced
apoptosis or immunologically-mediated cell death. Such questions are difficult to answer
due to limitations in experimental systems and the technical difficulties inherent in detecting
the low abundance of HCV antigen expressed by infected cells in human liver (Liang et al
2009).
A related question is whether the malignant cells in established HCC are productively
infected with HCV. The presence of viral RNA in HCC tissue is not a reliable marker of
infection in cancer cells, because potentially high numbers of virions circulate in the blood
and thus may be expected to be present in any vascular tissue. Importantly, most established
human hepatoma cell lines do not support the replication of HCV in cell culture. Such a lack
of permissiveness for HCV replication does not exclude a direct role for the virus in the
events leading to cancer, however, as the capacity of transformed hepatocytes to support
viral replication could be lost due to reduced expression of cellular co-factors required for
replication of HCV. As explained below, microRNA 122 (miR-122) is one such co-factor,
and it is often expressed at low levels in HCC. These observations do, however, indicate that
the malignant phenotype is unlikely to be driven directly by continued viral protein
expression, as in the case of papillomaviruses. Rather, they point to a cancer-promoting
effect of HCV infection.
While progression to HCC is variable among patients with chronic hepatitis C, suggesting
that cancer arises due to a complex interplay between host, viral and environmental factors,
a wealth of studies suggest that epigenetic changes in HCV-infected hepatocytes may
underlie the development of HCC. Here we summarize the evidence that HCV infection
leads to critical stresses on hepatocellular homeostasis and altered cellular response
pathways that promote the development of cancer above and beyond the nonspecific pro-
carcinogenic effects of cirrhosis and general hepatic inflammation. Such a hypothesis
suggests that cancer arises in infected cells and not in uninfected bystander hepatocytes, and
is consistent with the exceptionally high rate of HCC observed in HCV-related cirrhosis.
The HCV lifecycle
The HCV genome consists of a single-stranded, positive-sense RNA, approximately 9.6 kb
in length with untranslated RNA segments (UTRs) at both ends and a single large open
reading frame encoding a 327 kD polyprotein that is processed into 10 mature viral proteins
(Fig. 1) (for a review, see Lemon et al 2007). Most if not all of these viral proteins are
multifunctional. Indeed, the membrane-bound replicase complexes in which viral RNA is
synthesized contain less than 5% of the total complement of nonstructural proteins
expressed in cells (Quinkert et al 2005). In addition to their basic functions in supporting
viral genome amplification and the production of new virions, viral proteins interact with
host proteins in ways that facilitate genome amplification, antagonize host immune
responses, or otherwise alter the cellular environment to favor virus replication. Replication
of the virus is also dependent upon at least one cellular microRNA, miR-122, as discussed in
greater detail below. Many specific details are lacking, but viral RNA replication appears to
McGivern and Lemon Page 3













be an exclusively cytoplasmic process. This suggests that the mechanisms by which HCV
infection leads to cancer are likely to differ substantially from other models of viral
carcinogenesis. Nonetheless, HCV replication is associated with altered abundance or
localization of some typically nuclear proteins, including the retinoblastoma protein, Rb, and
DDX5 (p68) (Goh et al 2004, Munakata et al 2007).
Approaches to the study of HCV pathogenesis
Model systems
HCV is an hepatotropic virus and it replicates primarily if not exclusively within
hepatocytes. Some studies have suggested that there may be low level replication in
lymphocytes, and this has been well documented in cell culture (Shimizu et al 1998).
However, it is controversial whether this occurs in infected persons. There appear to be
multiple blocks to replication in peripheral blood mononuclear cells (Marukian et al 2008).
Other than humans, the only animal species that is fully permissive for HCV infection is the
chimpanzee, Pan troglodytes. HCV infection of the chimpanzee recapitulates most if not all
features of hepatitis C in humans. Although relatively small numbers of these primates have
been infected with HCV since the discovery of the virus, at least one chimpanzee has
developed HCC in the setting of chronic infection (Lanford et al 2011). This animal had
multiple tumors, but no cirrhosis and only minimal portal fibrosis. The chimpanzee
represents the only animal species in which viral pathogenesis can be accurately modeled,
but its availability at present for such studies is extremely limited.
There are no robust small animal models of HCV infection. A chimeric mouse model has
been developed in which human hepatocytes are transplanted into SCID/Alb-uPA mice
(Mercer et al 2001). In this system, liver-specific expression of the urokinase plasminogen
activator is toxic to the murine hepatocytes, allowing transplanted human hepatocytes to
repopulate the mouse liver. The human hepatocytes resident in the resulting chimeric liver
can be infected with HCV and this system has proven useful in studying certain aspects of
HCV replication. However, since the mice are immunodeficient, it is not possible to study
most host immune responses to the virus in these mice. In addition, this system is technically
challenging, the mice are not long-lived and they do not develop cancer. As a surrogate for a
small animal model of infection, a considerable number of transgenic mouse lines have been
developed that express various HCV proteins. These are discussed separately below.
Given the absence of a small animal that is permissive for replication of the virus, it is not
surprising that the influence of HCV protein expression on cellular homeostasis has been
studied mainly using in vitro systems. These include transient expression studies, the use of
cell lines containing HCV RNA replicons (i.e. cells that contain autonomously replicating,
selectable subgenomic or genome-length viral RNA but do not produce infectious virus)
(Lohmann et al 1999) (Fig. 1) and cell culture-infectious virus systems (Lindenbach and
Rice 2005, Wakita et al 2005, Yi et al 2006). Aside from the fact that all of these systems
are in vitro, each has its limitations. HCV proteins may be expressed by replicons at high
levels that are not physiologically relevant, and most replicon cell lines have been generated
from Huh-7 cells which express a mutant p53 (Bressac et al 1990). Moreover, the techniques
used to select such cell lines are likely to bias cell growth and survival properties. More
recently developed systems allowing the propagation of cell culture-produced HCV
(“HCVcc”) provide the most authentic in vitro system for studying the effects of HCV on
cellular homeostasis, but only two viral strains replicate well enough to study. Furthermore,
most cell lines that are known to be permissive for HCVcc replication are derived from
Huh-7 hepatoma cells. Despite these limitations, the cell culture-infectious virus systems
have allowed significant advances in understanding the role of HCV proteins in viral
replication and pathogenesis.
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HCV transgenic mice and HCC
Transgenic mouse models of HCV pathogenesis typically use liver-specific promoters to
drive expression of either individual or multiple HCV proteins. Although they lack viral
RNA replication, these transgenic mice provide insights concerning the potential
contribution of individual HCV proteins to liver disease and carcinogenesis. Table 1
summarizes HCV transgenic mouse lineages for which the phenotype has been determined
up until at least 12 months of age. Of these, only some lineages appear to be at risk for HCC.
The propensity of HCV transgenic mice to develop cancer varies with the mouse genetic
background, with C57BL/6 mice appearing to be most susceptible (Klopstock et al 2009). In
contrast, HCC has not been described in FVB mice expressing similar HCV transgenes. The
promoter used to drive expression of the HCV transgene, the nature of the transgene, as well
as the abundance of the HCV protein expressed also are likely to contribute to the presence
or absence of a cancer phenotype.
Most transgenic mouse lines express one or more of the HCV structural proteins. Two
transgenic lineages with high-level, liver-specific expression of the core protein developed
hepatic steatosis with progression to adenomas and HCC (Moriya et al 1998). No hepatic
inflammation was observed in these mice, suggesting a direct role for the core protein in
carcinogenesis. However, the level of transgene expression was very high in these mice, and
probably not reflective of the expression levels in most infected human livers. A separate
study demonstrated the development of cancer in mice transgenic for both core as well as
the two envelope proteins, E1 and E2 (Naas et al 2005). Although the promoter driving
transgene expression in these mice was not liver-specific, transgene mRNA levels were
highest in the liver. Steatosis was also observed in the livers of these mice, with the degree
of steatosis increasing with age. In older mice, hepatocellular adenomas and carcinomas
were observed, as well as tumors of lymphoid origin (Naas et al 2005).
In contrast to these mice, the FL-N/35 lineage expresses the entire HCV polyprotein under
the control of the albumin promoter (Lerat et al 2002). These mice have liver-specific
expression of the entire HCV polyprotein at very low abundance and thus may represent a
more physiologically relevant model of HCV-associated HCC. HCV proteins are detectable
in these mice only using very sensitive immunohistochemical methods (Keasler et al 2006),
and the expression level is likely to be closer to what it is in infected human tissues.
Steatosis was observed in these animals, but no inflammation, and liver cancer developed in
older male animals at a relatively low but statistically significant rate (Lerat et al 2002).
Interestingly, a companion transgenic mouse line, which expressed a greater abundance of
only the structural proteins, core, E1, E2, and p7, did not have a significantly increased
incidence of cancer compared to non-transgenic animals, suggesting a possible role for the
non-structural proteins in carcinogenesis (Lerat et al 2002). However, it is not possible to
exclude differences in the transgene integration sites underlying this difference. There are
few other reports of transgenic mice that express the nonstructural proteins of HCV, but
mice transgenic for the NS5A protein also develop significant steatosis and HCC (Wang et
al 2009a).
In addition to possible direct carcinogenic effects of HCV protein expression, studies with
transgenic mice have demonstrated that HCV protein expression may enhance susceptibility
to various nonchemical carcinogens. For example, the incidence of liver cancer in FL-N/35
polyprotein-expressing mice, is increased by iron overloading (Furutani et al 2006), co-
expression of the hepatitis B virus X protein (Keasler et al 2006), or intestinal colonization
with Helicobacter hepaticus (Fox et al 2010). Alcohol promoted the development of HCC in
NS5A transgenic mice that normally do not develop cancer (Machida et al 2009b, Majumder
et al 2003). The synergistic effects of alcohol and NS5A expression on the rate of tumor
formation were related to induction of TLR4 expression and a downstream mediator, Nanog.
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These findings are particularly interesting because alcohol ingestion increases the risk of
HCC in patients with chronic hepatitis C. In another series of experiments, a transgenic
mouse line expressing HCV core under control of the serum amyloid P component promoter
developed cancer only after repeated carbon tetrachloride-induced liver injury (Kato et al
2003). In this case, tumor development was dependent upon both repeated liver injury and
core protein expression. In contrast, transgenic expression of the viral structural proteins
resulted in an increase in tumor size, but not frequency, following exposure to
diethylnitrosamine (Kamegaya et al 2005).
In summary, cancer phenotypes in HCV transgenic mice suggest roles for both structural
and non-structural HCV proteins in hepatocellular carcinogenesis. The lack of detectable
inflammation in transgenic mice that develop cancer supports a direct role for HCV proteins
in carcinogenesis, while other evidence suggests that HCV protein expression may have
broader, co-carcinogenic effects. The variation evident in the phenotypes reported for HCV
transgenic mice is disconcerting, however. No single viral protein has been shown to
consistently cause liver cancer when expressed at a low abundance comparable to that
present in most patients with HCV-related liver disease.
General consequences of HCV infection
Inflammation, fibrosis and cirrhosis
Persistent HCV infections are typically associated with inflammatory and wound healing
responses within the liver. Activation of the NF-κB pathway plays a central role in these
inflammatory responses and may be important in carcinogenesis (reviewed in Sun and Karin
2008). Chronic inflammation related to HCV infection drives fibrogenesis, with increased
deposition of extracellular matrix proteins leading to fibrotic scarring and ultimately
cirrhosis. Activation of hepatic stellate cells (HSCs) is known to be important in this process
and may be cytokine-driven, but the specific mechanisms by which HCV infection induces
HSC activation are not well defined. Oxidative stress and apoptosis of infected hepatocytes
are likely to be contributory factors (Brenner 2009). Other studies suggest a pro-fibrotic role
for specific viral proteins (Bataller et al 2004, Mazzocca et al 2005) while yet others point to
immune responses as an important trigger (Baroni et al 1999).
The sensing of HCV infection by pathogen recognition receptors of the innate immune
system likely contributes to these processes. Viral double-stranded RNA replication
intermediates produced in infected hepatocytes are sensed by retinoic acid-inducible gene I
(RIG-I) and Toll-like receptor 3 (TLR3), leading to activation of interferon regulatory factor
3 (IRF-3) and NF-κB (Saito et al 2008, Wang et al 2009b). Although HCV has evolved
redundant mechanisms to counter these responses (reviewed in Lemon 2010), many patients
as well as chimpanzees with persistent HCV infection show marked transcriptional up-
regulation of interferon-stimulated genes. This may reflect the sensing of infected
hepatocytes by plasmacytoid dendritic cells through a TLR7-dependent pathway (Takahashi
et al 2010). In addition to these sensing mechanisms, other studies suggest that HCV-
induced endoplasmic reticulum stress (Waris et al 2002) or simply the presence of HCV-
encoded proteins may activate NF-κB signaling and the expression of pro-inflammatory
cytokines (Dolganiuc et al 2004, Sato et al 2006, Waris et al 2003). Core and NS3 stimulate
IL-1 receptor-associated kinase (IRAK) activity in multiple cell types, along with
phosphorylation of p38 and activation of extracellular regulated kinase (ERK) and c-jun N-
terminal kinase (JNK) kinases, via a TLR2-dependent pathway (Dolganiuc et al 2004) .
We have recently demonstrated that there is a patchy distribution of HCV infection within
the human liver, with infected cells generally appearing in clusters consistent with cell-to-
cell spread of virus (Liang et al 2009) (Fig. 2). Such cells do not always appear to be in close
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proximity to inflammatory cells, and interferons and other soluble mediators may largely
control spread through the liver. Nonetheless, virus-specific CD8+ cytotoxic T-cells are
present, and play a key role in controlling the infection (reviewed in Bowen and Walker
2005). Cytotoxic T cells and virus-induced inflammatory responses are likely to result in
repeated cycles of hepatocyte destruction and regeneration. This pattern of chronic
inflammation and increased hepatocellular proliferation provides an environment that is
highly conducive to the development of cancer, and is likely to be common to the
development of HCC due to many other causes. The link between chronic inflammation and
HCC is well established from transgenic models of hepatitis B (Nakamoto et al 1998), and it
seems certain that this link extends to HCV-associated cancer as well. However, several
complementary lines of evidence suggest that HCV also plays a direct role in development
of HCC.
Apoptosis
HCV infection may influence pathways that regulate programmed cell death. Numerous
over-expression studies have suggested both pro- and anti-apoptotic functions of individual
HCV proteins and have generated a large body of sometimes conflicting data. For example,
some reports purport that core protein expression promotes apoptosis (Chou et al 2005,
Honda et al 2000, Zhu et al 1998), while others suggest an anti-apoptotic effect of core
expression (Lu et al 1999, Ray et al 1998, Sacco et al 2003). In addition, E2 (Lee et al
2005), NS2 (Erdtmann et al 2003), NS3 (Tanaka et al 2006) and NS5A (Gale et al 1999, Lan
et al 2002) have all been reported to exert an anti-apoptotic effect when expressed in
cultured cells, while other studies suggest that NS3 (Prikhod'ko et al 2004) and NS4A
(Nomura-Takigawa et al 2006) may promote apoptosis. Most of these studies have evaluated
the effects of transient expression of individual HCV proteins at levels that may be
considerably higher than in infected hepatocytes in vivo. Core is a highly basic protein that
has been reported to have numerous pleiotropic effects when transiently over-expressed.
Moreover, the expression of individual HCV proteins in the absence of the remainder of the
polyprotein may lead to different localization or post-translational modifications than
expressed as a component of the viral polyprotein. Consequently, the biological significance
of these findings is not clear.
On the other hand, apoptosis has been demonstrated in response to HCV infection in more
physiologically relevant systems that have become available in recent years. For example,
recent reports have been consistent in demonstrating apoptosis in Huh-7 cells infected with
HCVcc (Deng et al 2008, Mateu et al 2008, Walters et al 2009). Furthermore, in the
chimeric SCID/Alb-uPA mouse model, apoptosis was observed in the transplanted human
hepatocytes following intrahepatic injection with replication-competent HCV RNA, but not
with a replication-defective mutant (Joyce et al 2009). Although HCV may replicate to
atypically high levels both in Huh7 cells as well as human hepatocytes within chimeric
livers of severely immunocompromised SCID/Alb-uPA mice, these studies suggest that
HCV infection may be inherently pro-apoptotic.
Steatosis
Hepatic steatosis, characterized by the intracellular accumulation of lipids in hepatocytes, is
frequently found in patients with chronic HCV infection (for a review, see Cross et al 2010).
Metabolic factors, such as high body mass index and diabetes, influence the development of
steatosis in chronic hepatitis C. However, there is a particularly strong association between
steatosis and infection with genotype 3 HCV, indicating that steatosis must result, at least in
part, from effects on the cell that are virus-specific. Consistent with this, transgenic mice
expressing genotype 1 HCV proteins, particularly core, develop steatosis (Lerat et al 2002,
Moriya et al 1997). Changes in the expression of lipid metabolism genes also have been
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observed in chimeric SCID/Alb-uPA mice infected with genotype 1 virus (Joyce et al 2009).
Whether directly virus-induced or metabolic in origin, steatosis may contribute to liver
cancer through increased oxidative stress or by promoting fibrosis.
Oxidative stress
Both microarray and proteomics studies have demonstrated increased expression of
oxidative stress response genes in HCV-associated fibrosis and cirrhosis (Diamond et al
2007, Shackel et al 2002). While no single causative mechanism has been unequivocally
identified, increased oxidative stress has the potential to cause DNA damage, potentially
leading to the accumulation of mutations, and may also activate HSC thereby promoting
fibrosis (Brenner 2009). Furthermore, chronic oxidative stress may lead to activation of
cellular signaling pathways that can contribute to cellular transformation (Waris et al 2005).
Oxidative stress has been detected in several models of HCV pathogenesis and is generated,
at least in part, by the inflammatory response to chronic infection. However, there may also
be a direct effect of HCV proteins, particularly core, on intracellular levels of reactive
oxygen species (ROS). Oxidative stress was observed in cultured cells following the
conditional expression of core protein under control of a tetracycline-regulated promoter
(Okuda et al 2002), and this led to increased expression of cellular antioxidant genes (Li et
al 2002). Transgenic mice expressing the core protein also show an increased abundance of
both ROS and lipid peroxidation products (Korenaga et al 2005, Moriya et al 2001). When
expressed in cultured cells, core protein localizes in part to mitochondria, and this may
promote increased ROS production through inhibition of mitochondrial electron transport
(Korenaga et al 2005). Other studies suggest that over-expression of NS5A may also cause
oxidative stress (Gong et al 2001), but the caveats described above for protein over-
expression studies must be considered in interpreting these results.
Epigenetic changes in gene expression accompanying HCV infection
The dependence of HCV upon a number of cellular proteins and even a microRNA for its
replication reflects extensive adaptation of the virus to its human host, a process shaped by
an extraordinarily high rate of virus production (on the order of 1012 new virus particles
produced every day over decades of persistent infection in the typical patient) (Neumann et
al 1998) and a highly error-prone RNA replicase. In addition to disrupting signal
transduction pathways involved in immune responses, these accessory functions of HCV
proteins appear to include a number of interactions with tumor suppressor proteins. Such
interactions are likely to have evolved because they promote a favorable cellular
environment for virus replication and thus survival of the virus. However, they may also
have coincidental, pathologic consequences for the host.
Retinoblastoma protein
The retinoblastoma tumor suppressor protein (Rb) is a common target of oncoproteins
expressed by DNA tumor viruses, including adenovirus (Whyte et al 1988), simian virus 40
(DeCaprio et al 1988), and human papillomavirus (Dyson et al 1989). The down-regulation
of Rb promotes cell cycle entry, activating cellular DNA synthetic pathways required for
replication of these viruses. Surprisingly, Rb is also targeted by HCV, an RNA virus, and
strongly, negatively regulated by HCV infection in cultured cells (McGivern et al 2009,
Munakata et al 2005, Munakata et al 2007). This is due to NS5B, the viral RNA-dependent
RNA polymerase, which forms a cytoplasmic complex with Rb (Fig. 3) and recruits to it the
E6-associated protein (E6AP). This leads to polyubiquitination of Rb and Rb degradation
via the proteasome (Munakata et al 2005, Munakata et al 2007). The end result is activation
of E2F-responsive promoters, which would be expected to stimulate entry into the S phase
of the cell cycle (Munakata et al 2005). In a fascinating parallel with DNA viruses, the
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interaction with Rb is dependent upon an LxCxE motif in NS5B that has homology to pRb-
binding domains in DNA virus oncoproteins (Munakata et al 2005).
These findings are unique among RNA viruses and suggest a novel theoretical framework
for the origins of liver cancer. In addition to controlling the G1 to S phase transition in the
cell cycle, in part through repressive effects on E2F transcription factors (Chellappan et al
1991, Classon and Harlow 2002, Takahashi et al 2000), Rb also regulates DNA damage
responses, the mitotic spindle checkpoint, and apoptosis (Classon and Harlow 2002,
Hernando et al 2004, Khidr and Chen 2006, Lentini et al 2002). While the virus might
benefit from enhanced hepatocellular proliferation (which might favor virus replication
based on observations in cell culture), the disruption of Rb-mediated regulatory functions
may also restrict DNA damage responses. Such a defect would be particularly important in a
liver with ongoing inflammation and oxidative stress. Expression of the core protein has also
been suggested recently to uncouple the mitotic spindle checkpoint and induce chromosomal
polyploidy in transgenic mice and cultured hepatocytes through defective Rb signaling
(Machida et al 2009a). In this case, Rb expression was thought to be restricted at the
transcriptional level.
The analogy with the DNA tumor viruses only goes so far, however. While the p16-cyclin
D-Rb pathway is frequently disrupted in HCC, including tumors associated with HCV
(Azechi et al 2001, Edamoto et al 2003), this does not result from continued virus replication
or NS5B expression. If it plays a role, NS5B-induced loss of Rb expression seems likely to
be an early event in the development of cancer, occurring while hepatocytes remain
sufficiently well differentiated to support virus replication, and prior to the heterogeneous
chromosomal mutations that are found commonly in HCC (Thorgeirsson and Grisham
2002).
p53 pathway
Over-expression studies suggest that HCV proteins, including core, may deregulate the p53
pathway. Again, however, the available experimental systems are limited and published
reports conflicting with respect to the effects on p53 activity. Some results suggest that core
activates p53-dependent gene expression (Lu et al 1999, Otsuka et al 2000) while others
show repression (Ray et al 1998). It is possible that this reflects varied levels of expression,
with low levels of core expression activating p53 and high levels resulting in repression of
p53 activity (Kao et al 2004). Other in vitro evidence suggests that NS3 may interact with
p53 (Ishido and Hotta 1998) and repress p53-dependent transcription (Kwun et al 2001).
NS3 expression blocks actinomycin D-induced apoptosis; this activity of NS3 was found to
be sequence-dependent and correlated with p53 interaction (Deng et al 2006, Tanaka et al
2006). Yet a third HCV protein, NS5A has been reported to interact with p53, resulting in its
redistribution to the perinuclear membrane in HepG2 hepatoma cells (Majumder et al 2001).
NS5A also interacts with p53 in the rat hepatoma cell line FAO, and inhibits p53-dependent
transcription in HCT116 cells (Qadri et al 2002). Anchorage-independent growth of
NIH3T3 cells is promoted by NS5A (Ghosh et al 1999). Finally, while ectopic expression of
p53 in the p53-null Hep3B cell line induces apoptosis, this effect is blocked by NS5A (Lan
et al 2002).
It is possible that HCV infection may also impact p53 function indirectly. As discussed in
greater detail below, there is good evidence that core interacts with the cellular RNA
helicase DDX3 (Fig. 4), a candidate tumor suppressor protein that regulates activity of the
p21(waf1/cip1) promoter (Chao et al 2006). In addition, NS5B interacts with DDX5 (p68),
another RNA helicase, resulting in its relocalization from the nucleus to the cytoplasm (Goh
et al 2004) (Fig. 5). DDX5 is a transcriptional co-activator of p53 (Bates et al 2005), a
function that would be impeded by its relocalization to the cytoplasm. Interactions of HCV
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proteins with the p53 pathway may have evolved to prevent stress-induced growth arrest or
apoptosis, both of which would be counter to survival of the virus. On the other hand, recent
studies have revealed surprising roles for p53 and DDX3 in TLR3 and RIG-I-mediated
induction of interferon synthesis (Dharel et al 2008, Oshiumi et al 2010, Schroder et al 2008,
Taura et al 2008), and it is possible that such interactions might reflect yet another
mechanism by which the virus escapes innate immune defenses.
Many of the immortalized cell lines used to study the impact of HCV protein expression on
p53 have defects in the p53 pathway. Huh-7 cells, which are commonly used for
propagation of HCV, overexpress a functionally defective p53 mutant (Bressac et al 1990).
To date, this has precluded a direct analysis of the effects of viral infection on p53 function
in cell culture. Similarly, NIH3T3, COS-7 and HeLa cells all express viral oncoproteins that
directly interact with the p53 protein. An additional consideration is that the level of protein
over-expression in many of these studies may be much higher than in the HCV-infected
liver. Therefore, while these findings may be relevant to the development of HCV-
associated HCC, they need to be interpreted with considerable caution.
Wnt/β-catenin
The Wnt pathway is a key signal transduction pathway in animal development. In the
canonical Wnt pathway, Wnt ligands bind to their receptor to activate a signal transduction
cascade resulting in inhibition of a β-catenin degradation complex. Components of the Wnt
pathway are frequently mutated in liver cancer, resulting in β-catenin stabilization.
Stabilization of β-catenin allows it to enter the nucleus and interact with proteins that
regulate transcription of genes that influence cell survival and proliferation.
NS5A may indirectly regulate the Wnt pathway through its interaction with the p85
regulatory subunit of phosphoinositide 3-kinase (PI3K), which results in activation of the
p110 catalytic subunit of PI3K and initiates signaling that activates the downstream kinase,
Akt (Street et al 2004). This leads in turn to phosphorylation and inactivation of glycogen
synthase kinase-3β(GSK-3β), a key component of the multiprotein complex that normally
targets β-catenin for proteasomal degradation (Street et al 2004). Thus, NS5A expression
results in the stabilization of β-catenin and increased β-catenin-dependent transcription
(Park et al 2009, Street et al 2005). Increases in β-catenin abundance have been observed in
cells containing autonomously replicating HCV replicons, and to some extent in cells
infected with HCVcc. More recent data, however, suggest that β-catenin may be activated
through a direct interaction with the NS5A protein (Milward et al 2010, Park et al 2009).
The functional significance of the activation of β-catenin within HCV infected cells is
uncertain. While dysregulation of Wnt signaling does not appear to be independently
capable of causing malignant transformation of hepatocytes, β-catenin abundance is
increased in most HCC and may promote tumor growth (reviewed in Whittaker et al 2010)
ATM and Chk2
The ataxia telangiectasia mutated kinase (ATM) is a tumor suppressor protein that detects
double-strand DNA breaks and regulates signal transduction pathways controlling the DNA
damage checkpoint. An interaction with the HCV NS3/4A protease results in partial
relocalization of ATM from the nucleus to the perinuclear region of the cytoplasm (Ariumi
et al 2008, Lai et al 2008). NS3/4A may also interact with another DNA damage sensor,
checkpoint kinase 2 (Chk2) (Ariumi et al 2008). Knockdown of either ATM or Chk2
impaired viral RNA replication and reduced virus yields, suggesting that these interactions
may have evolved to promote replication. Impaired ATM and Chk2 functions may explain
why NS3/4A expression results in abnormal responses to DNA damage following ionizing
radiation (Lai et al 2008).
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Among its many putative interactions, yeast two-hybrid screens and co-immunoprecipitation
studies have revealed a now well-documented interaction of the core protein with the DEAD
box RNA helicase, DDX3 (Mamiya and Worman 1999, Owsianka and Patel 1999, You et al
1999). This results in a profound change in the cellular distribution of DDX3, from what is
normally a diffuse, predominantly cytoplasmic distribution to punctate cytoplasmic foci that
co-localize with core protein in HCV-infected cells (Fig 4). DDX3 knock-down studies
suggest that it may specifically facilitate HCV replication (Ariumi et al 2007, Randall et al
2007). It is difficult to distinguish virus-specific effects of gene knockdown or over-
expression, however, from general pleiotropic effects on the cell that may indirectly
influence replication, as shown recently in studies of another cellular helicase, DDX6 (Rck/
p54), which also interacts with core (Jangra et al 2010a). At any rate, the ability of DDX3 to
modulate HCV replication is independent of its core-binding activity (Angus et al 2010).
Like many DEAD-box helicases, DDX3 appears to be multifunctional. As described above,
it regulates activity of the p21(waf1/cip1) promoter and represses cap-dependent translation
through inhibition of eIF4E (Chao et al 2006, Shih et al 2008), and may have significant
tumor suppressor activity (Botlagunta et al 2008, Chang et al 2006). However, DDX3 is also
required for efficient induction of interferons in response to virus infections (Oshiumi et al
2010, Schroder et al 2008), and this may be the function underlying its targeting by HCV.
Innate immune signaling
Like many other viruses, HCV has evolved mechanisms to antagonize host innate immune
signaling pathways (reviewed in Lemon 2010). These pathways are closely linked to tumor
suppressor functions, as alluded to above, and the long term targeting of innate immune
signaling pathways by viral proteins during persistent infection may result in the promotion
of cell growth and inhibition of apoptosis. The dsRNA-activated protein kinase (PKR) is
interferon-inducible and down-regulates translation via phosphorylation of eIF-2α, thereby
inhibiting cell growth and promoting apoptosis to restrict virus infection. These properties
confer tumor-suppressor activity on PKR (Meurs et al 1993). In vitro data suggest that the
NS5A protein can bind to and functionally repress PKR (Gale and Katze 1998, Gale et al
1997), possibly contributing to oncogenesis via this pathway (Gale et al 1999). In addition to
the effects of HCV on PKR, the NS3/4A protease targets essential adapter molecules in both
the TLR3 and RIG-I signaling pathways, TIR-domain containing inducer of interferon-β
(TRIF) and mitochondrial antiviral signaling protein (MAVS, also known as IPS-1), thereby
interfering with activation of IRF-3 (Li et al 2005a, Li et al 2005b, Meylan et al 2005, Wang
et al 2009b), a transcription factor with strong anti-proliferative properties (Kim et al 2003).
These interactions evolved to protect the virus from the antiviral actions of numerous IRF-3
dependent genes, including type I interferons, but may also contribute to the cancer-
promoting effects of HCV.
Growth factor signaling
Growth factor signaling pathways play important roles in the initiation and possibly
maintenance of HCC (reviewed in Whittaker et al 2010). The transforming growth factor
beta (TGF-β) signaling pathway exerts both an anti-proliferative and pro-apoptotic
influence, and is important in regulating the expansion of progenitor cells in regenerating
liver (Thenappan et al 2010). The HCV core protein has been suggested to interact with
Smad3, a transcriptional modulator that is activated through the TGF-β pathway, thereby
impairing the tumor suppressive properties of TGF-β (Battaglia et al 2009, Cheng et al
2004, Pavio et al 2005). In addition, NS5A has the capacity to interact with Src homology 3
(SH3) domains that are found in many proteins involved in signal transduction. Such
interactions may involve Grb2, an adaptor protein involved in growth factor signaling (Tan
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et al 1999), the p85 subunit of PI3K, as described above (Street et al 2004), and some
members of the Src tyrosine kinase family (Macdonald et al 2004).
miRNAs and HCV-associated cancer
miRNAs are likely to play important roles in both the causation and maintenance of cancers,
including HCC (Coulouarn et al 2009, Pineau et al 2010). Of 940 recognized human
miRNAs, miR-122 is uniquely expressed at high abundance in the adult liver, representing
approximately 50% of miRNAs and with 50,000 or more copies per cell (Chang et al 2004).
It is developmentally regulated and expressed almost exclusively in liver, controlling the
expression of numerous hepatocyte-specific genes and promoting hepatocellular
differentiation (Chang et al 2004, Elmen et al 2008, Krutzfeldt et al 2005).
HCV replication is critically dependent upon miR-122 (Jangra et al 2010b, Jopling et al
2005). miR-122 binds to two conserved, tandem sites in the HCV 5′UTR that are
complementary to its “seed” sequence (Jopling et al 2008). This interaction is required for
effective genome amplification, but available data do not suggest that it directly enhances
viral RNA synthesis (Jopling et al 2005, Norman and Sarnow 2010). Instead, miR-122
binding promotes cap-independent translation of the viral RNA (Henke et al 2008, Jangra et
al 2010b). However, the magnitude of this effect appears insufficient to completely explain
the dependence of HCV on miR-122, and thus the requirement for miR-122 as a host factor
for HCV replication remains incompletely explained. Importantly, however, HCV
replication was potently suppressed in chimpanzees after therapeutic silencing of miR-122
by administration of an antisense locked nucleic acid (LNA) oligonucleotide against
miR-122 (Lanford et al 2010). These recent data have fueled enthusiasm for miR-122
antagomirs as potential antiviral agents, making a better understanding of the role of
miR-122 in carcinogenesis imperative.
There is some evidence that miR-122 may have tumor suppressor properties. Expression of
miR-122 is low or undetectable in the human hepatoma cell lines, Hep3B and HepG2 cells,
in which its over-expression inhibits anchorage-independent growth, migration, invasion,
and tumor formation in nude mice (Bai et al 2009). IL-1α is one of many genes regulated by
miR-122, and polymorphisms in the miR-122 binding site in the IL-1α 3′UTR confer an
increased risk for HCC (Gao et al 2009). Cyclin G1 is also regulated by miR-122,
influencing the stability of p53 and affecting the growth properties of HCC-derived cells
(Fornari et al 2009). Although a number of studies have profiled miRNA expression in
HCC, it remains unclear whether miR-122 abundance is altered in HCV-associated HCC.
Overall, miR-122 expression is reduced in 50-70% of HCC (Gramantieri et al 2007, Kutay
et al 2006, Ura et al 2009). However, it may be increased in a subset of HCC with mutations
in β-catenin (Pineau et al 2010), and some but not all studies suggest that miR-122
expression is preserved specifically in HCV-associated cancers (Coulouarn et al 2009, Ura
et al 2009, Varnholt et al 2008). This is an important question that deserves further study, as
loss of miR-122 would limit the ability of HCV to replicate in HCC cells.
Despite the unique relationship between HCV and miR-122, few studies have examined how
HCV infection influences miR-122 expression. Acute infection of Huh-7 cells with HCVcc
was reported recently to cause a significant decline in miR-122 abundance (Liu et al 2010).
Many other miRNAs were differentially regulated by HCV infection in this study, however,
and it is difficult to predict how these results relate to infection of normal hepatocytes in
vivo. miRNA biogenesis is modulated by p53 through an interaction with the Drosha
processing complex that involves an association with DDX5 (Suzuki et al 2009). Since
various HCV proteins interact with both p53 and DDX5, as described above, it is not
surprising to find that HCV infection might alter global miRNA expression profiles.
However, the lack of normal p53 function in Huh-7 cells mandates a great deal of caution in
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interpreting the results of such studies. There are large gaps in our understanding of how
HCV regulates miRNA expression, and the role of miRNAs in development of HCC. Future
studies should be directed at addressing these questions.
Summary and conclusions: A model of HCV-associated
hepatocarcinogenesis
Although HCV is increasingly associated with HCC in the U.S. and probably many other
countries, attempts to understand the underlying pathogenetic mechanisms are limited by the
absence of good cellular and animal models of HCV pathogenesis. Those data that are
available suggest that HCV-associated HCC is likely to be caused by a combination of
environmental, epigenetic and genetic factors. In patients who are chronically infected with
HCV, cancer typically develops in the setting of cirrhosis. Repeated cycles of immune-
mediated destruction of infected hepatocytes and virus-induced apoptosis together with
regeneration of damaged tissue cause disturbances in the normal cellular homeostasis of the
liver. Furthermore, inflammatory responses associated with persistent infection cause
oxidative stress that can damage chromosomal DNA, leading to heritable changes in the
genome. These processes mirror the development of HCC due to many other causes.
However, the occurrence of HCV-associated HCC in the absence of cirrhosis, the
particularly high rate of HCC in cirrhosis caused by chronic HCV infection, and the
development of HCC in HCV transgenic mice in the absence of inflammation or fibrosis,
suggest that persistent HCV infection and viral protein expression is likely to have a direct
cancer-promoting effect. Numerous interactions between viral proteins and cellular tumor
suppressor pathways may act not only to further viral replication, but also to deregulate
normal control of the cell cycle and cellular responses to DNA damage. These cancer-
promoting actions of HCV may be eliminated largely if not completely by effective antiviral
therapy. Antiviral therapies remain limited in efficacy, however, and a better understanding
of the effects of HCV infection on these regulatory pathways may suggest new opportunities
for preventive measures that may be taken in the absence of virus eradication.
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HCV genome structure. (top) Organization of the positive-sense RNA genome of HCV. 5′
and 3′ UTRs contain cis-acting elements required for viral protein expression and RNA
synthesis, including an internal ribosome entry site (IRES) in the 5′UTR that directs cap-
independent translation of the viral polyprotein. The polyprotein (large box) is processed by
both host and virus-encoded proteases to produce the individual proteins required for viral
genome replication, virus assembly, and production of infectious progeny virus (reviewed in
Moradpour et al 2007). The structural proteins (blue) that form the HCV virion include core
(nucleocapsid), E1 and E2 (envelope glycoproteins). Non-structural proteins of HCV serve a
variety of functions including RNA genome replication, virus assembly and maturation:
those from NS3-NS5B (pink) are required for genome replication. NS3 has distinct
proteinase and helicase domains, while NS4A is cofactor that intercalates with NS3 and is
required for full expression of NS3 protease activity. NS4B is involved in the formation of
the membranous web: a cytoplasmic structure associated with the viral RNA replicase.
NS5A is an essential co-factor for virus replication and assembly, while NS5B is the viral
RNA-dependent RNA polymerase. p7 and NS2 (green) are additional nonstructural proteins
that are not required for viral RNA synthesis but contribute to virion assembly and egress.
(bottom) Organization of a dicistronic, selectable HCV “replicon”. The 5′ and 3′UTRs are
as in the viral genome. A truncated core-protein sequence is fused to the neomycin
phosphotransferase gene, followed downstream by a heterologous picornaviral IRES driving
translation of the nonstructural proteins. This RNA is capable of autonomous amplification
in permissive cells, but does not generate infectious virus.
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HCV core antigen visualized in frozen liver tissue from a 50 year old female with genotype
3 HCV infection, cirrhosis, and a serum viral RNA load of 3.3 × 105 IU/ml. Tissue was
collected at the time of resection of HCC. Antigen was visualized by multiphoton
microscopy following tissue labeling with a monoclonal antibody to core conjugated to a
fluorescent quantum dot probe (Liang et al 2009).
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Laser-scanning confocal microscopy of FT3-7 (Huh7) cells infected with HCVcc (HJ3-5
virus) leads to reductions in nuclear Rb expression (left panel, arrow) and transient
accumulation of Rb in the cytoplasm (arrows, right panel). HCV antigens (red) were labeled
with polyclonal human anti-HCV antibodies, while Rb was labeled with a murine
monoclonal antibody (green) (McGivern et al 2009). Nuclei were counterstained with DAPI.
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Confocal microscopic image showing aggregation of DDX3 in association with HCV core
protein in the cytoplasm of HCVcc-infected cells. Huh7 cells were infected with HJ3-5 virus
11 days previously. Labeling was with rabbit anti-core (green) and murine anti-DDX3 (red)
antibodies (gifts of Dr. Arvind Patel, Medical Research Council Virology Unit, Glasgow).
Nuclear counterstain was with DAPI. Mock = mock infected.
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DDX5 is redirected from the nucleus to the cytoplasm in Huh7 cells infected with HCVcc
(JFH1 strain). Cells were labeled with murine anti-DDX5 (red) and human polyclonal anti-
HCV (green) antibodies. Nuclei were counterstained with DAPI. Mock = mock infected.
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